Literature DB >> 27348743

Longitudinally extensive transverse myelitis: A retrospective analysis of sixty-four patients at tertiary care center of North-West India.

Rajendra Singh Jain1, Sunil Kumar2, Tarun Mathur3, Shankar Tejwani4.   

Abstract

OBJECTIVES: To evaluate the demographic profile, clinical presentations, laboratory parameters and etiologies of longitudinally extensive transverse myelitis (LETM) patients in Indian population. PATIENTS AND METHODS: LETM is characterized by contiguous inflammatory lesions of spinal cord extending to three or more vertebral segments. Neuromyelitis optica (NMO) is the most common cause of LETM. In clinical practice, both LETM and NMO are thought to be synonymous with each other because of their very frequent association. Other causes of LETM are infective, neoplastic, autoimmune diseases and connective tissue disorders. All other causes should be ruled out before making the diagnosis of NMO in LETM patients. We conducted a retrospective study from August 2010 to February 2016 and analyzed various demographic profile, clinical presentations, laboratory parameters and etiologies in sixty-four patients of LETM.
RESULTS: In our series, majority of the patients presented with acute bladder dysfunction and paraparesis. Twenty-one patients (32.81%) were clinically diagnosed as NMO, out of which thirteen patients were found to have positive serum NMO antibody. Other etiologies of LETM in our series were multiple sclerosis [9 patients], acute disseminated encephalomyelitis (ADEM) [6 patients], postinfectious [5 patient], subacute combined degeneration (SCD) [4 patient], tuberculous myelitis [4 patients], spinal arteriovenous malformation (AVM) [3 patient] and systemic lupus erythematosus (SLE) [3 patient], respectively. In nine patients, cause could not be ascribed despite thorough investigations.
CONCLUSION: LETM is a heterogeneous disorder with a varied clinical feature, etiologies and outcome. Even the LETM patients who presented with optic neuritis do not necessarily have NMO. Therefore, the diagnosis of NMO should be made only after excluding other causes of LETM. The presence of NMO-Ab (Aquaporin 4-Ab) predicts the increased risk of recurrence of LETM or conversion to NMO.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aquaporin-4 antibodies; Longitudinally extensive transverse myelitis; NMO antibodies; Neuromyelitis optica

Mesh:

Year:  2016        PMID: 27348743     DOI: 10.1016/j.clineuro.2016.06.011

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

1.  Longitudinally extensive transverse myelitis with pulmonary tuberculosis: Two case reports.

Authors:  Yu Zhang; Mingqin Zhu; Lifang Wang; Miao Shi; Hui Deng
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

2.  Herpes Simplex Virus Type 2 Myelitis: Case Report and Review of the Literature.

Authors:  Raffaele Nardone; Viviana Versace; Francesco Brigo; Frediano Tezzon; Giulio Zuccoli; Slaven Pikija; Larissa Hauer; Johann Sellner
Journal:  Front Neurol       Date:  2017-05-10       Impact factor: 4.003

3.  Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies.

Authors:  Sunanda Paudel; Gaurav Nepal; Sandesh Guragain; Sangam Shah; Basanta S Paudel; Rajeev Ojha; Reema Rajbhandari; Ragesh Karn; Bikram P Gajurel; Sunanda Paudel
Journal:  Cureus       Date:  2021-03-18

4.  Pulmonary Tuberculosis with Longitudinally Extensive Transverse Myelitis.

Authors:  Kiran Kumar Ramineni; Ravi Kanth Jakkani; B V G Swamy; Sravan Kumar M
Journal:  J Neurosci Rural Pract       Date:  2020-03-03

5.  Long Spinal Cord Lesions Caused by Venous Congestive Myelopathy Associated with Intravascular Large B-cell Lymphoma.

Authors:  Takeshi Miura; Shoji Saito; Rie Saito; Tomohiro Iwasaki; Naomi Mezaki; Tomoe Sato; Yoichi Ajioka; Akiyoshi Kakita; Takuya Mashima
Journal:  Intern Med       Date:  2021-06-19       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.